- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05451004
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer (SELECT)
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial
This study is being done to answer the following question:
Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Wendy Parulekar
- Phone Number: 613-533-6430
- Email: wparulekar@ctg.queensu.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Recruiting
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
Contact:
- Site Public Contact
- Phone Number: 416-480-5000
-
Principal Investigator:
- Antoine Eskander
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- University Health Network-Princess Margaret Hospital
-
Contact:
- Site Public Contact
- Phone Number: 416-946-4501
- Email: clinical.trials@uhn.on.ca
-
Principal Investigator:
- Ali Hosni
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Recruiting
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contact:
- Site Public Contact
- Phone Number: 819-820-6480
- Email: crcinformation.chus@ssss.gouv.qc.ca
-
Principal Investigator:
- Isabelle Gauthier
-
-
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Recruiting
- Baptist MD Anderson Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 904-202-7468
-
Principal Investigator:
- Omar M. Mahmoud
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 305-243-2647
-
Principal Investigator:
- Gregory J. Kubicek
-
Tampa, Florida, United States, 33607
- Recruiting
- Moffitt Cancer Center-International Plaza
-
Contact:
- Site Public Contact
- Phone Number: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
Principal Investigator:
- Krupal B. Patel
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center - McKinley Campus
-
Contact:
- Site Public Contact
- Phone Number: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
Principal Investigator:
- Krupal B. Patel
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-679-0775
- Email: ClinicalTrials@moffitt.org
-
Principal Investigator:
- Krupal B. Patel
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Recruiting
- Emory University Hospital Midtown
-
Contact:
- Site Public Contact
- Phone Number: 888-946-7447
-
Principal Investigator:
- Jill Remick
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Site Public Contact
- Phone Number: 312-695-1301
- Email: cancer@northwestern.edu
-
Principal Investigator:
- Katelyn Stepan
-
Warrenville, Illinois, United States, 60555
- Recruiting
- Northwestern Medicine Cancer Center Warrenville
-
Contact:
- Site Public Contact
- Phone Number: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Principal Investigator:
- Katelyn Stepan
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan Comprehensive Cancer Center
-
Principal Investigator:
- Steven B. Chinn
-
Contact:
- Site Public Contact
- Phone Number: 800-865-1125
-
Brighton, Michigan, United States, 48116
- Recruiting
- University of Michigan - Brighton Center for Specialty Care
-
Principal Investigator:
- Steven B. Chinn
-
Contact:
- Site Public Contact
- Phone Number: 800-865-1125
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- UNC Lineberger Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Principal Investigator:
- Xuguang Chen
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Recruiting
- Providence Portland Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Principal Investigator:
- Charles W. Drescher
-
-
Texas
-
Conroe, Texas, United States, 77384
- Recruiting
- MD Anderson in The Woodlands
-
Contact:
- Site Public Contact
- Phone Number: 866-632-6789
- Email: askmdanderson@mdanderson.org
-
Principal Investigator:
- Anna Lee
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Principal Investigator:
- Anna Lee
-
Houston, Texas, United States, 77079
- Recruiting
- MD Anderson West Houston
-
Contact:
- Site Public Contact
- Phone Number: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Principal Investigator:
- Anna Lee
-
League City, Texas, United States, 77573
- Recruiting
- MD Anderson League City
-
Contact:
- Site Public Contact
- Phone Number: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Principal Investigator:
- Anna Lee
-
Sugar Land, Texas, United States, 77478
- Recruiting
- MD Anderson in Sugar Land
-
Contact:
- Site Public Contact
- Phone Number: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Principal Investigator:
- Anna Lee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with pathologically proven diagnosis of lateralized OPC (tonsil, tongue base, soft palate, or pharyngeal wall) not involving or crossing midline.
- HPV positive or negative (by p16 immunohistochemistry).
- Clinical stage T1-3 M0 (UICC/AJCC TNM 8th Edition). Nodal involvement may include no nodes or single or multiple ipsilateral lymph nodes (largest ≤6cm in maximum diameter)
Radiological investigations within 8 weeks of registration:
- CT or MRI of the neck (with head imaging as indicated);
- PET-CT scan
- Chest CT scan
- Planned definitive RT or CRT with bilateral neck RT (patients planned for unilateral neck RT are excluded).
- Intent to deliver concurrent chemotherapy or not must be known at the time of randomization. As this is a pragmatic trial, even patients who are not candidates for systemic therapy will be eligible for participation.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Willing to complete the quality of life and/or health utility questionnaire, if sufficiently fluent in available language(s).
- Informed consent prior to registration
- Accessible for treatment and follow-up.
- Commencement of definitive RT within 28 days (+ 14 days) of randomization.
- Injection procedure for lymphatic mapping may be performed in the nuclear medicine, ambulatory clinic, or operating room setting
- Women/men of childbearing potential must have agreed to use a highly effective contraceptive method
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Patient must consent to provision of, and investigator(s) must confirm location and commitment to obtain a representation of formalin fixed paraffin block of non-cytology tumour tissue in order that the specific correlative marker assays
Exclusion Criteria:
- T1-T2 cancers isolated to the tonsil fossa (i.e. without any soft palate, tongue base, posterior pharyngeal wall or posterior tonsil pillar involvement) with no involved lymph nodes or with a single ipsilateral node < 3 cm without extranodal extension.
- Tonsil or tongue base primary cancer who have previously undergone diagnostic palatine or lingual tonsillectomy with either complete excision or with no clinically apparent residual disease
- Previous head and neck cancer or multiple synchronous primary head and neck cancers
- Previous induction or neo-adjuvant chemotherapy.
- Previous radiation therapy to the head and neck or comprehensive neck dissection of at least 3 levels on either side (due to potential for disrupted lymphatic channels and drainage pathways). Patients who have had excisional biopsies of involved lymph nodes are eligible
- Radiotracer allergy
Severe, active co-morbidity including any of the following:
- Chronic Obstructive Pulmonary Disease or other pulmonary illness requiring hospitalization within 30 days of registration
- Unstable angina and/or congestive heart failure requiring hospitalization within the 30 days of registration
- Acute myocardial infarction within 30 days of study registration
- Diseases precluding RT (e.g. scleroderma)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lympathic Mapping with SPECT-CT guided Radiotherapy
|
Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
|
Active Comparator: Bilateral Neck Radiotherapy
|
Radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease-free Survival
Time Frame: 8 years
|
8 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life using M.D. Anderson Dysphagia Inventory (MDADI)
Time Frame: 8 years
|
Possible range of scores between 0 and 100 (higher scores indicating better swallowing and lower score indicating poor swallowing).
|
8 years
|
Xerostomia-related Quality of Life using Xerostomia Questionnaire (XQ)
Time Frame: 8 years
|
Clinically meaningful worsening of xerostomia (10 units on XQ) from baseline to 12 months post RT
|
8 years
|
Isolated contralateral neck failure (iCNF)
Time Frame: 8 years
|
8 years
|
|
Overall Survival (OS)
Time Frame: 8 years
|
8 years
|
|
Logo-regional Failure (LRF)
Time Frame: 8 years
|
8 years
|
|
Distant Metastases (DM)
Time Frame: 8 years
|
8 years
|
|
Incidence and Severity of Radiation-related Toxicities
Time Frame: 8 years
|
8 years
|
|
Patient-Reported Toxicities using PRO CTCAE
Time Frame: 8 years
|
8 years
|
|
Gastrostomy Tube Usage
Time Frame: 8 years
|
8 years
|
|
Resource Utilization
Time Frame: 8 years
|
8 years
|
|
Lost Productivity
Time Frame: 8 years
|
Healthcare system and societal resources will be quantified over the course of the trial to generate utilization information by patient in each study arm.
We will generate an average cost per study subject by treatment arm for an overall mean cost per study arm
|
8 years
|
Financial Toxicity [Financial Index of Toxicity (FIT)]
Time Frame: 8 years
|
8 years
|
|
Health Utilities using EQ-5D
Time Frame: 8 years
|
8 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: John R de Almeida, University Health Network, Princess Margaret Hospital, Toronto ON Canada
- Study Chair: Ali Hosni, University Health Network, Princess Margaret Hospital, Toronto ON Canada
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCTG-HN11 (Other Identifier: NCI/CTEP)
- NCI-2022-04496 (Other Identifier: NCI CTRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oropharyngeal Cancer
-
Wake Forest University Health SciencesTerminatedHead and Neck Cancer | Stage I Laryngeal Cancer | Stage II Laryngeal Cancer | Stage I Hypopharyngeal Cancer | Stage I Oropharyngeal Cancer | Stage II Hypopharyngeal Cancer | Stage II Oropharyngeal Cancer | Stage III Hypopharyngeal Cancer | Stage III Laryngeal Cancer | Stage III Oropharyngeal Cancer | Stage... and other conditionsUnited States
-
Lisette NixonStanford University; University of Leipzig; AdventHealth; UNICANCER; Princess Alexandra...RecruitingHuman Papillomavirus (HPV)-Positive Oropharyngeal CancerGermany, United Kingdom, United States, Australia, France
-
University of FloridaTerminatedOropharyngeal CancersUnited States
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina
-
M.D. Anderson Cancer CenterRecruitingOropharyngeal CarcinomaUnited States
-
NexImmune Inc.Not yet recruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Cancer | Human Papilloma Virus | Head and Neck Cancer Metastatic | HPV-Related Squamous Cell Carcinoma | Oropharyngeal Cancer, Metastatic | HPV-Related Mucosal Head and Neck Squamous... and other conditions
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingTongue Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell CarcinomaUnited States, Canada, Saudi Arabia, Ireland
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Effects of Chemotherapy | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina
-
Emory UniversityNational Cancer Institute (NCI)RecruitingClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal HPV-Positive Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States
Clinical Trials on Lymphatic Mapping with SPECT-CT
-
M.D. Anderson Cancer CenterCompletedCervical CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedCervical Cancer | Endometrial Cancer | Cervical CarcinomaUnited States
-
M.D. Anderson Cancer CenterTerminated
-
N.N. Petrov National Medical Research Center of...RecruitingColon CancerRussian Federation
-
Thomas GuerreroCompletedPulmonary Embolism | Pulmonary ThromboembolismsUnited States
-
The Netherlands Cancer InstituteRecruiting
-
UMC UtrechtWithdrawn
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
-
University Hospital, EssenActive, not recruiting
-
Dana-Farber Cancer InstituteCompleted